M&A Deal Summary

Cephalon Acquires Anesta

On July 17, 2000, Cephalon acquired life science company Anesta for 444M USD

Acquisition Highlights
  • This is Cephalon’s 1st transaction in the Life Science sector.
  • This is Cephalon’s 2nd largest (disclosed) transaction.
  • This is Cephalon’s 1st transaction in the United States.
  • This is Cephalon’s 1st transaction in Utah.

M&A Deal Summary
Date 2000-07-17
Target Anesta
Sector Life Science
Buyer(s) Cephalon
Deal Type Merger
Deal Value 444M USD

Target

Anesta

Salt Lake City, Utah, United States
Anesta is a developer of new oral transmucosal pharmaceutical products. In addition to its lead product, ACTIQ, the company has other investigational product candidates in clinical development including: OTS(TM) nicotine for smoking cessation, OTS fentanyl for acute pain management, OTS etomidate for short-acting sedation, OTS piroxicam for mild to moderate pain, OTS droperidol and OTS prochlorperazine for nausea and vomiting, and OTS scopolamine for motion sickness.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Cephalon

Frazer, Pennsylvania, United States
Category Company
Founded 1987
Sector Life Science
Employees3,726
DESCRIPTION

Cephalon is a global biopharmaceutical company dedicated to discovering, developing and bringing to market medications to improve the quality of life of individuals around the world. Since its inception in 1987, Cephalon has brought first-in-class and best-in-class medicines to patients in several therapeutic areas.

DEAL STATS #
Overall 1 of 7
Sector (Life Science) 1 of 7
Type (Merger) 1 of 1
State (Utah) 1 of 1
Country (United States) 1 of 4
Year (2000) 1 of 1
Size (of disclosed) 2 of 6
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2005-06-14 Salmedix

San Diego, California, United States

Salmedix was a late stage biopharmaceutical company focusing on in-licensing and development of cancer products. The Company?s lead product, SDX-105, was in Phase II/III clinical trials for non-Hodgkin?s lymphoma at the time of Easton's investment. In addition, Salmedix had two drugs in Phase II clinical development, as well as several preclinical product candidates.

Buy $160M
Mergr

Product

Company

Legal